SCCM’s COVID-19 Rapid Resource Center now links to pertinent content from the Centers for Disease Control and Prevention (CDC). These resources are categorized as Pharmacology
The information provided is for educational purposes for SCCM members and the general public. Clicking on these links allows users to leave www.sccm.org. The Society does not control the linked sites or the content on those sites. SCCM does not assume any liability for the content or information contained on these linked sites. Further, SCCM does not assume any liability or warrant with respect to the quality, noninfringement, accuracy, completeness, timeliness, or reliability of such linked sites.You should be aware that other internet sites that link to the Site may contain privacy provisions that differ from these policies. To ensure that your privacy is protected, we recommend that you review the privacy policies of other internet sites you visit.
Morbidity and Mortality Weekly Report (MMWR) Weekly / June 24, 2022 / 71(25);830-833 — Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment — California, December 2021-May 2022
Date Added: 9/13/2022
The Food and Drug Administration and a small number of published case reports have documented recurrence of COVID-19 symptoms or a positive viral test result (COVID-19 rebound) days after recovery or a negative SARS-CoV-2 test result among patients treated with Paxlovid; however, large-scale studies investigating severe illness after Paxlovid treatment are limited. This study used electronic health record data from a large integrated health care system in California (Kaiser Permanente Southern California [KPSC]) to describe hospital admissions and emergency department encounters related to SARS-CoV-2 infections during the 5–15 days after pharmacy dispensation of a 5-day treatment course of Paxlovid.
COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021
Date Added: 2/4/2022
Previous reports of COVID-19 case, hospitalization, and death rates by vaccination status† indicate that vaccine protection against infection, as well as serious COVID-19 illness for some groups, declined with the emergence of the B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, and waning of vaccine-induced immunity. During August–November 2021, CDC recommended§ additional primary COVID-19 vaccine doses among immunocompromised persons and booster doses among persons aged ≥18 years. The SARS-CoV-2 B.1.1.529 (Omicron) variant emerged in the United States during December 2021 and by December 25 accounted for 72% of sequenced lineages. To assess the impact of full vaccination with additional and booster doses (booster doses), case and death rates and incidence rate ratios (IRRs) were estimated among unvaccinated and fully vaccinated adults by receipt of booster doses during pre-Delta (April–May 2021), Delta emergence (June 2021), Delta predominance (July–November 2021), and Omicron emergence (December 2021) periods in the United States.
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Date Added: 2/4/2022
Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months because of waning vaccine induced immunity over time, possible increased immune evasion by SARS-CoV-2 variants, or a combination of these and other factors. CDC recommends that all persons aged ≥12 years receive a third dose (booster) of an mRNA vaccine ≥5 months after receipt of the second mRNA vaccine dose and that immunocompromised individuals receive a third primary dose. A third dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine increases neutralizing antibody levels, and three recent studies from Israel have shown improved effectiveness of a third dose in preventing COVID-19 associated with infections with the SARS-CoV-2 B.1.617.2 (Delta) variant. Yet, data are limited on the real-world effectiveness of third doses of COVID-19 mRNA vaccine in the United States, especially since the SARS-CoV-2 B.1.1.529 (Omicron) variant became predominant in mid-December 2021.
What Clinicians Need to Know About the New Oral Antiviral Medications for COVID-19
Date Added: 2/4/2022
The emergency use authorizations (EUAs) for the new oral antiviral medications molnupiravir and Paxlovid™ (nirmatrelvir/ritonavir) supplement current therapeutic efforts to decrease hospitalizations and prevent severe COVID-19 and death. During this COCA Call, presenters from the Centers for Disease Control and Prevention (CDC), Office of the Assistant Secretary for Preparedness and Response, U.S. Food and Drug Administration (FDA), and the National Institutes of Health (NIH) will describe the recent EUAs and NIH treatment guidelines, patient prioritization, and resources for healthcare providers.
COCA Call - What Clinicians Need to Know About the New Oral Antiviral Medications for COVID-19
Date Added: 1/21/2022
The emergency use authorizations (EUAs) for the new oral antiviral medications molnupiravir and Paxlovid™ (nirmatrelvir/ritonavir) supplement current therapeutic efforts to decrease hospitalizations and prevent severe COVID-19 and death. During this COCA Call, presenters from CDC, the Office of the Assistant Secretary for Preparedness and Response, U.S. Food and Drug Administration (FDA), and the National Institutes of Health (NIH) described the recent EUAs and NIH treatment guidelines, patient prioritization, and resources for healthcare providers.
Pediatric COVID-19 Vaccines: CDC’s Recommendations for Pfizer-BioNTech COVID-19 Vaccine Primary Series in Children 5–11 Years Old
Date Added: 11/15/2021
COCA Call: Pediatric COVID-19 Vaccines: CDC’s Recommendations for Pfizer-BioNTech COVID-19 Vaccine Primary Series in Children 5–11 Years Old — During this COCA call, CDC provided an overview of its recommendations and clinical considerations for administering the Pfizer-BioNTech COVID-19 vaccination primary series in children aged 5–11 years old.
What Clinicians Need to Know about the Recent Updates to CDC’s Recommendations for COVID-19 Boosters (webinar)
Date Added: 11/15/2021
This COCA call will provide an overview of the most recent recommendations for administering COVID-19 booster vaccines. The Centers for Disease Control and Prevention will provide updates about the latest recommendations and clinical considerations for administering COVID-19 boosters, including an update on early safety monitoring for additional COVID-19 vaccine doses.
Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19
Date Added: 9/27/2021
HAN Archive: Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19
Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data — United States, March 2020–January 2021
Date Added: 9/27/2021
Morbidity and Mortality Weekly Report (MMWR) detailing the association between COVID-19 and Myocarditis.
Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States
Date Added: 9/27/2021
CDC now recommends that people aged 65 years and older, residents in long-term care settings, and people aged 50–64 years with underlying medical conditions should receive a booster shot of Pfizer-BioNTech’s COVID-19 Vaccine at least 6 months after completing their Pfizer-BioNTech primary series. Other groups may receive a booster shot based on their individual risk and benefit. Learn more.
COCA Call: What Clinicians Need to Know About Pfizer-BioNTech COVID-19 Vaccination of Adolescents
Date Added: 5/21/2021
The Clinician Outreach and Communication Activity (COCA) held a call Friday, May 14, 2021, from 2:00–3:00 p.m. (Eastern Time). During this COCA call, participants received an overview of the Pfizer-BioNTech COVID-19 vaccination in adolescents who are 12-to-15 years of age. Participants also learned about the safety and efficacy of the vaccine, vaccine recommendations, and clinical guidance for using the Pfizer-BioNTech COVID-19 vaccine in adolescents in this age group.
CDC COVID-19 Resource: Johnson & Johnson/Janssen COVID-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome (TTS): Update for Clinicians
Date Added: 5/12/2021
The Clinician Outreach and Communication Activity (COCA) held a call Tuesday, April 27, 2021, from 2:00–3:00 p.m. (Eastern Time). During this COCA Call, participants received the latest evidence on thrombosis with thrombocytopenia syndrome (TTS) after administration of the Johnson & Johnson/Janssen COVID-19 vaccine. Speakers discussed information on TTS and updated vaccine recommendations.
ACIP Presentation Slides: February 28 - March 1, 2021 Meeting
Date Added: 3/4/2021
This is a link to the CDC external resources regarding COVID-19. This link covers the latest ACIP Guidelines regarding the COVID-19 vaccines.
COVID-19 Vaccine FAQs for Healthcare Professionals
Date Added: 2/17/2021
This link covers COVID-19 Vaccine FAQs for healthcare professionals.
National Healthcare Safety Network (NHSN) Factsheet: Tracking Healthcare-Associated Infections (HAIs), and Antibiotic Resistance (AR) Infections
Date Added: 2/4/2021
CDC’s National Healthcare Safety Network is supporting the nation’s COVID-19 response by providing a domestic tracking and response system to identify emerging and enduring threats across healthcare, such as COVID-19, healthcare-associated infections (HAIs), and antibiotic-resistant (AR) infections.
Frequently Asked Questions about COVID-19 Vaccination in Long-Term Care Facilities
Date Added: 1/20/2021
This is a link to the CDC COVID-19 external resource regarding frequently asked questions about COVID-19 vaccination in long-term care facilities.
Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States
Date Added: 1/12/2021
This is a link to the CDC COVID-19 external resource regarding interim clinical considerations for sse of mRNA COVID-19 vaccines currently authorized in the United States.
Moderna COVID-19 Vaccine
Date Added: 1/6/2021
This is a link to the CDC COVID-19 external resource regarding interim recommendation for use of Moderna COVID-19 vaccine.
COVID-19 Podcast - The Latest on the COVID-19 Vaccine
Date Added: 1/6/2021
How safe and efficient are the current COVID-19 vaccine candidates? How are public health systems and health care providers preparing for vaccine administration? Buddy Creech, MD, and Kathryn Edwards, MD, FIDSA, of Vanderbilt University and Dial Hewlett, MD, FIDSA, of the Westchester County Department of Health answer those questions and more.
Report an Adverse Event to VAERS
Date Added: 1/6/2021
The Vaccine Adverse Event Reporting System (VAERS) is a passive reporting system, meaning it relies on individuals to send in reports of their experiences. Anyone can submit a report to VAERS, including parents and patients.
Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites
Date Added: 1/6/2021
Anaphylaxis is an acute and potentially life-threatening serious allergic reaction. These clinical considerations provide information on preparing for the initial assessment and management of anaphylaxis following COVID-19 vaccination.
What Clinicians Need to Know About the Pfizer-BioNTech COVID-19 Vaccine
Date Added: 12/21/2020
Information regarding what clinicians need to now about the Pfizer-BioNTech COVID-19 vaccine.
Frequently Asked Questions about COVID-19 Vaccination
Date Added: 12/21/2020
The CDC updates frequently asked questions for Healthcare Infection Prevention and Control and Healthcare Professionals regularly based on feedback from professionals on the ground.
This information is provided is for educational purposes for SCCM members and the general public. Clicking on these links allows users to leave www.sccm.org. The Society does not control the linked sites or the content on those sites. SCCM does not assume any liability for the content or information contained on these linked sites. Further, SCCM does not assume any liability or warrant with respect to the quality, noninfringement, accuracy, completeness, timeliness, or reliability of such linked sites.You should be aware that other internet sites that link to the Site may contain privacy provisions that differ from these policies. To ensure that your privacy is protected, we recommend that you review the privacy policies of other internet sites you visit.
COVID-19 Vaccine Training Module for Healthcare Providers
Date Added: 12/21/2020
A new web-on-demand module, COVID-19 Vaccine Training Module for Healthcare Providers, is now available for healthcare providers who will be administering COVID-19 vaccine. The training includes information about COVID-19 vaccine emergency use authorizations, vaccine safety, and general information about vaccine storage, handling, administration, and reporting.
Vaccine Storage and Handling Toolkit
Date Added: 12/21/2020
Best Practices on Vaccine Storage and Handling – An Addendum with best practices and other resources has been added to CDC’s Vaccine Storage and Handling Toolkit to assist COVID-19 vaccination providers with proper storage and handling of COVID-19 vaccines and aims to help providers meet the requirements of the COVID-19 Vaccination Program Provider Agreement. The Addendum will be updated with specific information for each COVID-19 product.
Estimated Time: